Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Daniel Wolff, Corey Cutler, Stephanie J Lee...
https://pubmed.ncbi.nlm.nih.gov/39292927/Actively Recruiting
Led by Syndax Pharmaceuticals · Updated on 2026-06-16
296
Participants Needed
121
Research Sites
229 weeks
Total Duration
This trial is a Phase 2 study evaluating axatilimab, an antibody targeting the colony stimulating factor 1 receptor, in participants aged 2 years and older with recurrent or refractory active chronic graft versus host disease cGVHD. These participants have previously received at least two lines of systemic therapy but still have active disease requiring further treatment. The study aims to assess the efficacy, safety, and tolerability of axatilimab at different dose levels in this population. Participants will be randomly assigned to one of three axatilimab dosing regimens administered intravenously. The doses include 0.3 mgkg every two weeks, 1 mgkg every two weeks, or 3 mgkg every four weeks. Treatment cycles last 28 days and may continue for up to two years. This open-label, multicenter study allows participants to receive axatilimab while being closely monitored. During the study, participants will have regular assessments to evaluate treatment response based on established NIH criteria for cGVHD. Researchers will measure overall response rates in the first six cycles as well as throughout the study period of up to two years. Other evaluations include symptom scales, organ-specific responses, medication use changes, laboratory biomarkers, and safety monitoring. Participants are followed for efficacy, tolerability, and adverse events during treatment and for the full study duration.
CONDITIONS
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
S
Syndax Pharmaceuticals
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Syndax Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Lower Dose Axatilimab | Intermediate Dose Axatilimab | Higher Dose Axatilimab |
|---|---|---|---|
| What is it? | Axatilimab given at a lower dose, a high-affinity antibody targeting CSF-1R, aiming to manage cGVHD by modulating macrophage activity. | Axatilimab administered at an intermediate dose, with the same mechanism targeting CSF-1R and intended for disease control in cGVHD. | Axatilimab at a higher dose, utilizing CSF-1R inhibition to regulate macrophage involvement and cGVHD progression. |
| Role in trial | Assigned as an investigational treatment arm to evaluate response and safety at the lower dose. | Assigned as a treatment arm to observe efficacy and tolerability at the intermediate dose. | Assigned as a trial arm to monitor response and safety at the higher dose. |
| Primary use | Evaluated for efficacy and safety in controlling refractory or recurrent cGVHD. | Assessed for efficacy and tolerability in patients with cGVHD resistant to prior systemic therapies. | Used to determine effectiveness and safety in difficult-to-treat cGVHD cases. |
| How is it given or performed? | Axatilimab is given in a scheduled dosing regimen as designated per cohort protocol, delivered intravenously; exact dose and schedule are defined by trial arm. | Administered intravenously at intermediate preset doses according to trial-defined schedule; dosing details follow the cohort’s protocol. | Delivered as an intravenous infusion at the highest trial dose; administered according to stringent schedule under study protocol. |
| Evidence status | Preliminary published results show that Axatilimab provides responses in patients with refractory or recurrent cGVHD, with immune modulation as a key mechanism. | Reported evidence indicates that Axatilimab at intermediate doses is active in treating cGVHD, with therapeutic effects shown across various organ systems. | Published evidence demonstrates clinical responses for higher dose Axatilimab in tough-to-treat cGVHD, though comparative information for dosing effects is still emerging. |
| Important limitations | Long-term safety and optimal dosing remain uncertain, as evidence is still limited to interim and early phase results. | Known limitations include lack of definitive guidance on dose selection and the need for additional study of durability of response. | Comparisons between dosing cohorts are still ongoing, and limited published evidence restricts interpretation of risk-benefit balance among dose levels. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants receive one of three axatilimab dosing regimens intravenously every 2 or 4 weeks. Treatment cycles last 28 days and may continue for up to 2 years.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Daniel Wolff, Corey Cutler, Stephanie J Lee...
https://pubmed.ncbi.nlm.nih.gov/39292927/Yan-Ou Yang, Victor Sokolov, Alina Volkova...
https://pubmed.ncbi.nlm.nih.gov/39704205/Syndax Pharmaceuticals
Lead Sponsor